Your browser doesn't support javascript.
loading
Loss of FGFR4 promotes the malignant phenotype of PDAC.
D'Agosto, Sabrina; Pezzini, Francesco; Veghini, Lisa; Delfino, Pietro; Fiorini, Claudia; Temgue Tane, Gael D; Del Curatolo, Anais; Vicentini, Caterina; Ferrari, Giorgia; Pasini, Davide; Andreani, Silvia; Lupo, Francesca; Fiorini, Elena; Lorenzon, Giulia; Lawlor, Rita T; Rusev, Borislav; Malinova, Antonia; Luchini, Claudio; Milella, Michele; Sereni, Elisabetta; Pea, Antonio; Bassi, Claudio; Bailey, Peter; Scarpa, Aldo; Bria, Emilio; Corbo, Vincenzo.
Afiliação
  • D'Agosto S; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Pezzini F; Human Technopole, Milan, Italy.
  • Veghini L; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Delfino P; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Fiorini C; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Temgue Tane GD; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Del Curatolo A; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Vicentini C; ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
  • Ferrari G; ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
  • Pasini D; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Andreani S; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Lupo F; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Fiorini E; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Lorenzon G; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Lawlor RT; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Rusev B; ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
  • Malinova A; ARC-Net Research Centre, University and Hospital Trust of Verona, Verona, Italy.
  • Luchini C; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Milella M; Department of Diagnostics and Public Health, University and Hospital Trust of Verona, Verona, Italy.
  • Sereni E; Department of Medicine, Section of Oncology, University and Hospital Trust of Verona, Verona, Italy.
  • Pea A; Department of Surgery, University and Hospital Trust of Verona, "Pancreas Institute", Verona, Italy.
  • Bassi C; Department of Surgery, University and Hospital Trust of Verona, "Pancreas Institute", Verona, Italy.
  • Bailey P; Department of Surgery, University and Hospital Trust of Verona, "Pancreas Institute", Verona, Italy.
  • Scarpa A; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
  • Bria E; Cancer Research UK Beatson Institute, Glasgow, UK.
  • Corbo V; Department of General Surgery, University of Heidelberg, Heidelberg, Germany.
Oncogene ; 41(38): 4371-4384, 2022 09.
Article em En | MEDLINE | ID: mdl-35963908
ABSTRACT
Transcriptomic analyses of pancreatic ductal adenocarcinoma (PDAC) have identified two major epithelial subtypes with distinct biology and clinical behaviours. Here, we aimed to clarify the role of FGFR1 and FGFR4 in the definition of aggressive PDAC phenotypes. We found that the expression of FGFR4 is exclusively detected in epithelial cells, significantly elevated in the classical PDAC subtype, and associates with better outcomes. In highly aggressive basal-like/squamous PDAC, reduced FGFR4 expression aligns with hypermethylation of the gene and lower levels of histone marks associated with active transcription in its regulatory regions. Conversely, FGFR1 has more promiscuous expression in both normal and malignant pancreatic tissues and is strongly associated with the EMT phenotype but not with the basal-like cell lineage. Regardless of the genetic background, the increased proliferation of FGFR4-depleted PDAC cells correlates with hyperactivation of the mTORC1 pathway both in vitro and in vivo. Downregulation of FGFR4 in classical cell lines invariably leads to the enrichment of basal-like/squamous gene programs and is associated with either partial or full switch of phenotype. In sum, we show that endogenous levels of FGFR4 limit the malignant phenotype of PDAC cells. Finally, we propose FGFR4 as a valuable marker for the stratification of PDAC patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma de Células Escamosas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncogene Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Carcinoma de Células Escamosas / Carcinoma Ductal Pancreático Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Oncogene Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália